Navigation Links
Data to be presented at AAN Meeting -Study results of drug,candidate for MS

06;355:1124-40).

Conclusion/Relevance: Evaluation of depression in MS may contribute to the assessment of overall effects of innovative treatments. At M6, fewer patients receiving FTY720, compared with PL, reported depression on the BDI-II or as an AE. Mean BDI-II scores were low in all groups. Nevertheless, patients receiving FTY720 1.25 mg, compared with PL, showed significant improvement in this score between baseline and M6.

2) [P07.101] CNS Mediated Effects of FTY720 (Fingolimod) in EAE

Date: Thursday, May 3, 2007 11:30 AM

Location: Exhibit Hall A - Poster Sessions VII: Multiple Sclerosis and Related Diseases: Animal Models II (11:30 AM - 2:30 PM)

Objective: To determine the centrally mediated effects of FTY720 (Fingolimod) in experimental autoimmune encephalomyelitis (EAE) in DA rats, an animal model of multiple sclerosis.

Conclusion/Relevance: These studies suggest that the mechanism of action of FTY720 may involve beneficial direct CNS effects in addition to the well-described effect on reducing T cell infiltration into the CNS. This raises the possibility that FTY720 might also have protective effects in progressive stages of multiple sclerosis.

3) [P08.135] FTY720 (Fingolimod) Regulates Astrocyte Signaling and Migration

Date: Thursday, May 3, 2007 4:00 PM

Location: Exhibit Hall A - Poster Sessions VIII: Multiple Sclerosis and Related Diseases: Immunology II (4:00 - 7:00 PM)

Objective: The aim of our study was to define which sphingosine-1-phosphate receptor (S1P-Rs) subtypes are responsible for mediating FTY720 action on brain cells, specifically on astrocytes.

Conclusion/Relevance: We report that FTY720P activates S1P-Rs on astrocytes, thereby stimulating a number of intracellular signals and cell migration. These findings indicate that FTY720 has multiple S1P-R-specific modes of action, beyond immunomodulation, which may contribute to its effectiveness in multiple sclerosis.


'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007
2. Data supporting three Antisoma programmes presented at AACR
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
6. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Data presented AAN Meeting Study results drug candidate for
(Date:8/27/2008)...ionally Recognized Pediatric Heart Center at The C...s for Community to Complete Range of Care and ...Recruited Pediatric Cardiology Team Treats Every H...ewswire/ -- The Children,s Hospital at,Montefiore ...c heart,transplantation to the Bronx, following th...
(Date:8/26/2008)...SALEM, Ore., Aug. 26 /- The Oregon To...ity Care Customer Service Training Program,(Q Care...gon Q Care is a training program created to suppor...anced employee education. By emphasizing,the impor...ll equip,employees with tools and resources to bet...
(Date:8/26/2008)...INDIANAPOLIS, Aug. 26 /- Semafore Pha...Seventh International Congress on Targeted,Therapi...al antiangiogenic,activity of vascular-targeted PI... VEGF and Bv8 signaling., PI3K is part of a very ...as been shown to play a major role in cancer. Stud...
(Date:8/26/2008)...Study finds most patients can drive safely six wee...Aug. 26 /PRNewswire-USNewswire/ -- Six weeks follo...e so low that they are able to,get back behind the...gust,2008 issue of The Journal of Bone and Joint S...ergency brake time response in patients who underw...
Breaking Medicine Technology:Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4Oregon Tourism Commission Unveils New Online Customer Service Training Program 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3Braking After Bunion Surgery 2Braking After Bunion Surgery 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 1Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 5MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 1MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 2MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 1CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 4Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 1Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 2
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ty Massey Cancer Center have discovered a process ...cules containing platinum, which causes HIV and ca...the researchers to develop new drugs to fight HIV ...argeting proteins known as zinc fingers. In the M...
...at funds for wheelchair service from NHS has not r...ildren are losing out their hope due to lack of a ...wheelchair with most basic parts, was given due to...sh Me Around!’, highlights. Thus it calls for Gove...
...n (NBA) have entered into a partnership to support.... // The campaign, 'Unite for Children, Unite aga.../AIDS on children as well as impeding further spre...e know that our sport, indeed all sports, has an e...
...hetamine-like stimulant has a calming effect on ch...er (ADHD) // . A new study undertaken on rats, se...ly used to treat ADHD, appears to work by tweaking...acted by any stimuli from the outside world. The s...
Other Medicine News:Health News:New Research May Be Useful for Developing Drugs for HIV and Cancer 2Health News:Ritalin Could Help In Focussing The Mind 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: